SummaryRMgm-615
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21625465 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii YM |
Name parent line/clone | Not applicable |
Other information parent line | P. yoelii YM is a virulent strain of P. yoelii |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | D. Bapat; P.R. Preiser |
Name Group/Department | School of Biological Sciences |
Name Institute | Nanyang Technological University |
City | Singapore |
Country | Singapore |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-615 |
Principal name | PYΔpy01365(NF1); PYΔpy01365(NF2) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | The mutant showed a different (delayed) course of parasitemia in BALB/c mice and BALB/c mice showed a delayed death from infection. Mutant blood stages showed a restricted host cell range. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation The pehenotype of an independent mutant lacking expression of PY01365 (RMgm-405) has been reported. The phenotype of this mutant is different from the phenotype reported in this study (see 'Additional Information' below). Additional information A significant percentage (35-41%) of mutant schizonts stained with mAb 25.77 confirming that the protective 25.77 antibody does not only recognize a single variant of Py235. Quantitative RT-PCR analyses indicate that disruption of PY01365 leads to a change in the overall transcription pattern of different members of Py235. In an independent study the phenotype has been analysed from an independent P. yoelii mutant lacking expression of PY01365 (see RMgm-405). Host cell preference (reticulocytes, normocytes), growth/multiplication rate of asexual blood stages of this mutant was NOT different from wild type parasites. Evidence is presented that there was no compensatory significant upregulation of expression of any of the other Py235 genes in the mutant parasite. For this mutant it has been suggested that that the protein PY01185 is able to fulfill the role of PY01365 by serving as an invasion ligand. Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1468100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | Not available | ||||||||||||||||||||||||
Gene product | Not available | ||||||||||||||||||||||||
Gene product: Alternative name | 235EBP-1; Py235EBP-1; erythrocyte binding protein 1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | The 10178bp genomic locus MALPY00360, coding for py01365, was targeted by a double cross-over strategy. The 5' and 3' target regions are located between nucleotides 1545 - 2162 and 4729 - 5312 respectively. No information is provided on the primers used for amplification of the target regions | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |